{"log_id": 1999033440435141605, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.003415, "average": 0.985241, "min": 0.637877}, "location": {"width": 817, "top": 229, "height": 30, "left": 204}, "words": "哺乳妇女:美国疾病控制和预防中心建议,HIV-1感染的妇女不应以母乳喂养她们的"}, {"probability": {"variance": 0.008105, "average": 0.968626, "min": 0.557155}, "location": {"width": 823, "top": 259, "height": 27, "left": 204}, "words": "婴儿,以避免出生后HIV-1传播的风险。在人类中,取自产后一周内的五名HIV-1感"}, {"probability": {"variance": 7.4e-05, "average": 0.997468, "min": 0.947632}, "location": {"width": 816, "top": 287, "height": 29, "left": 205}, "words": "染妇女的乳液样本显示,替诺福韦被分泌到人乳中。这种暴露对哺乳期婴儿的影响尚"}, {"probability": {"variance": 7.4e-05, "average": 0.996274, "min": 0.962054}, "location": {"width": 816, "top": 317, "height": 27, "left": 205}, "words": "未明确。因为HIV-1传播和严重的不良反应都有可能在哺乳婴儿中发生,所以母亲如"}, {"probability": {"variance": 8e-06, "average": 0.998254, "min": 0.987747}, "location": {"width": 707, "top": 346, "height": 29, "left": 204}, "words": "果正在接受富马酸替诺福韦二吡呋酯治疗,应当要求她们不要以母乳喂养"}, {"probability": {"variance": 0, "average": 0.999572, "min": 0.999156}, "location": {"width": 94, "top": 399, "height": 27, "left": 211}, "words": "儿童用药"}, {"probability": {"variance": 0.000107, "average": 0.994892, "min": 0.941854}, "location": {"width": 817, "top": 451, "height": 27, "left": 204}, "words": "研究115中,106名 Hbeag阴性(9%)和阳性(91%)12至18岁以下慢性HBV感染受"}, {"probability": {"variance": 0.00773, "average": 0.975814, "min": 0.542768}, "location": {"width": 825, "top": 479, "height": 28, "left": 205}, "words": "试者随机接受富马酸替诺福韦二吡呋酯300mg(N=52)或安慰剂(N=54)双盲治"}, {"probability": {"variance": 0.003316, "average": 0.978445, "min": 0.722728}, "location": {"width": 803, "top": 508, "height": 27, "left": 204}, "words": "疗72周。研究入选时,平均 HBV DNA.值为8.11og10 copies/mL,平均ALT值为101"}, {"probability": {"variance": 1.8e-05, "average": 0.997435, "min": 0.980724}, "location": {"width": 809, "top": 538, "height": 27, "left": 205}, "words": "U/L。富马酸替诺福韦二吡呋酯组52名受试者中,20名核苷/核苷酸初治受试者,32"}, {"probability": {"variance": 0.000194, "average": 0.995074, "min": 0.928976}, "location": {"width": 809, "top": 566, "height": 28, "left": 204}, "words": "名核苷/核苷酸经治受试者。32名核苷/核苷酸经治受试者中31人接受过拉米夫定治"}, {"probability": {"variance": 3.7e-05, "average": 0.995941, "min": 0.972126}, "location": {"width": 838, "top": 596, "height": 27, "left": 204}, "words": "疗。72周时,富马酸替诺福韦二吡呋酯组88%(46/52)受试者和安慰剂组0%(0/54)"}, {"probability": {"variance": 0.000307, "average": 0.992399, "min": 0.914001}, "location": {"width": 809, "top": 624, "height": 27, "left": 205}, "words": "受试者达 HBV DNA<400 copies/mL。基线时ALT异常的受试者中,富马酸替诺福韦"}, {"probability": {"variance": 0.000447, "average": 0.992718, "min": 0.860623}, "location": {"width": 799, "top": 653, "height": 26, "left": 206}, "words": "二吡呋酯组74%(26/35)受试者在第72周时ALT复常,而安慰剂组为31%(13/42)"}, {"probability": {"variance": 0.000262, "average": 0.995508, "min": 0.901732}, "location": {"width": 781, "top": 681, "height": 28, "left": 205}, "words": "受试者。富马酸替诺福韦二吡呋酯治疗组1名受试者在研究前72周期间出现持续"}, {"probability": {"variance": 0.001112, "average": 0.988782, "min": 0.878314}, "location": {"width": 282, "top": 713, "height": 26, "left": 206}, "words": " HBSAG转阴和抗HBs血清转换"}, {"probability": {"variance": 1.3e-05, "average": 0.997831, "min": 0.983626}, "location": {"width": 825, "top": 761, "height": 29, "left": 205}, "words": "富马酸替诺福韦二吡呋酯在12岁以下或体重低于35kg的慢性乙肝儿童患者中的安全"}, {"probability": {"variance": 0, "average": 0.999455, "min": 0.997977}, "location": {"width": 199, "top": 792, "height": 26, "left": 205}, "words": "性和有效性尚未确定"}, {"probability": {"variance": 0.000191, "average": 0.988954, "min": 0.960734}, "location": {"width": 113, "top": 842, "height": 29, "left": 211}, "words": "[老年人用药"}, {"probability": {"variance": 1.4e-05, "average": 0.997702, "min": 0.983507}, "location": {"width": 800, "top": 891, "height": 27, "left": 206}, "words": "富马酸替诺福韦二吡呋酯的临床试验没有入选足够数量的年满65岁或以上的受试者"}, {"probability": {"variance": 1.7e-05, "average": 0.998328, "min": 0.978208}, "location": {"width": 814, "top": 919, "height": 28, "left": 207}, "words": "无法判定他们的应答是否与较年轻的受试者的应答不同。一般而言,老年患者选择剂"}, {"probability": {"variance": 5.9e-05, "average": 0.997769, "min": 0.952562}, "location": {"width": 814, "top": 948, "height": 28, "left": 206}, "words": "量应当谨慎,切记他们肝、肾、心功能下降,并发疾病或正在使用其他药物治疗的几"}, {"probability": {"variance": 0, "average": 0.999531, "min": 0.999145}, "location": {"width": 67, "top": 980, "height": 25, "left": 206}, "words": "率增加"}, {"probability": {"variance": 7.9e-05, "average": 0.992509, "min": 0.974873}, "location": {"width": 146, "top": 1031, "height": 26, "left": 211}, "words": "[药物相互作用]"}, {"probability": {"variance": 9e-06, "average": 0.99793, "min": 0.988334}, "location": {"width": 814, "top": 1078, "height": 29, "left": 206}, "words": "富马酸替诺福韦二吡呋酯与去羟肌酐联合给药时应当谨慎,接受联合用药的患者应当"}, {"probability": {"variance": 1e-05, "average": 0.998706, "min": 0.981834}, "location": {"width": 792, "top": 1107, "height": 29, "left": 206}, "words": "密切监测与去羟肌酐有关的不良事件。在出现与去羟肌酐相关的不良反应的患者中"}, {"probability": {"variance": 1e-06, "average": 0.999073, "min": 0.996665}, "location": {"width": 177, "top": 1138, "height": 25, "left": 205}, "words": "应当停用去羟肌酐"}, {"probability": {"variance": 0.000286, "average": 0.995358, "min": 0.892937}, "location": {"width": 810, "top": 1183, "height": 30, "left": 208}, "words": "与富马酸替诺福韦二吡呋酯联合给药时,去羟肌酐的最大血清浓度(Cmax)和血浆浓"}, {"probability": {"variance": 2.7e-05, "average": 0.997312, "min": 0.97239}, "location": {"width": 820, "top": 1213, "height": 28, "left": 209}, "words": "度时间曲线下面积(AUC)显著升高(参见“药代动力学”)。这种相互作用的机制尚"}, {"probability": {"variance": 5e-06, "average": 0.998918, "min": 0.989403}, "location": {"width": 813, "top": 1239, "height": 29, "left": 208}, "words": "未明确。较高的去羟肌酐浓度有可能导致与去羟肌酐有关的不良反应,包括胰腺炎和"}, {"probability": {"variance": 1.5e-05, "average": 0.998055, "min": 0.982556}, "location": {"width": 807, "top": 1271, "height": 27, "left": 209}, "words": "神经病变。在接受富马酸替诺福韦二吡呋酯和去羟肌酐每天400mg的患者中,观察"}, {"probability": {"variance": 0.023878, "average": 0.946424, "min": 0.457969}, "location": {"width": 210, "top": 1302, "height": 25, "left": 208}, "words": "到CD4*细胞计数下降"}, {"probability": {"variance": 0.000336, "average": 0.995319, "min": 0.884692}, "location": {"width": 824, "top": 1348, "height": 32, "left": 211}, "words": "在体重>60kg的患者中,与富马酸替诺福韦二吡呋酯联用时,去羟肌酐肠溶剂的剂"}, {"probability": {"variance": 2.7e-05, "average": 0.996556, "min": 0.974406}, "location": {"width": 859, "top": 1376, "height": 54, "left": 208}, "words": "量应当减至每天250m在体重<60kg的患者中,与富马酸替诺福韦二吡呋酯联用"}], "language": 3}